Over the years, several anti-uPA and anti-uPAR compounds have been developed and tested both in vitro and in animal tumor models, some of which showed effectiveness in preclinical studies and also in phase I/II clinical trials [18,30]. This evidence concerns the gene PLAU and neoplasm.